Home > Insider Trading > Filing (0001127602-13-009363)

Filing Details

Accession Number:: 0001127602-13-009363
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-05 17:27:45
Reporting Period:: 2013-03-01

Filing Date:: 2013-03-05
Accepted Time:: 2013-03-05 17:27:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1395777	Duane Desisto	C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-03-01	20,000	$3.60	161,666	No	4	M	Direct
Common Stock	Disposition	2013-03-01	20,000	$22.06	141,666	No	4	S	Direct
Common Stock	Disposition	2013-03-01	11,374	$23.40	130,292	No	4	F	Direct
Common Stock	Acquisiton	2013-03-01	60,000	$0.00	190,292	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	F	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-03-01	20,000	$0.00	20,000	$3.60
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2013-03-01	30,000	$0.00	30,000	$23.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,527		2015-02-09	No	4	M	Direct
30,000		2023-03-01	No	4	A	Direct

Footnotes

Includes an aggregate of 8,367 shares acquired under the Insulet Corporation Amended and Restated 2007 Employee Stock Purchase Plan on the following dates: 219 shares acquired on December 31, 2007; 694 shares acquired on June 30, 2008; 1,429 shares acquired on December 31, 2008; 1,431 shares acquired on June 30, 2009; 772 shares acquired on December 31, 2009; 749 shares acquired on June 30, 2010; 732 shares acquired on December 31, 2010; 532 shares acquired on June 30, 2011; 640 shares acquired on December 30, 2011; 580 shares acquired on June 29, 2012; and 589 shares acquired on December 31, 2012.
Includes 13,334 restricted stock units granted on March 1, 2011 which vest on March 1, 2014; and 70,000 restricted stock units granted on April 1, 2012 which vest one-quarter of the total units on April 1, 2013, one-quarter of the total units on April 1, 2014, one-quarter of the total units on April 1, 2015 and one-quarter of the total units on April 1, 2016. Vested shares will be delivered to the reporting person as soon as practiable following a vesting date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2012.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $21.98 to $22.25. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations.
The 60,000 restricted stock units vest one-quarter of the total units on March 1, 2014, one-quarter of the total units on March 1, 2015, one-quarter of the total units on March 1, 2016 and one-quarter of the total units on March 1, 2017. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
This option may be exercised at any time, whether vested or not, but, upon termination of employment, we may repurchase any unvested shares at the exercise price paid for the shares. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal monthly installments each month thereafter for 36 months, subject to continued employment.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.